GIP (Glucose-Dependent Insulinotropic Polypeptide)
An incretin hormone that, alongside GLP-1, stimulates insulin secretion in response to nutrient intake. Tirzepatide is a dual GIP/GLP-1 receptor agonist, distinguishing it from pure GLP-1 agonists.
What does GIP (Glucose-Dependent Insulinotropic Polypeptide) mean in peptide research?
An incretin hormone that, alongside GLP-1, stimulates insulin secretion in response to nutrient intake. Tirzepatide is a dual GIP/GLP-1 receptor agonist, distinguishing it from pure GLP-1 agonists. This term is part of the broader field of peptide research, which encompasses both FDA-approved therapeutic peptides and research-grade compounds used in scientific investigation.
Why this term matters
Understanding GIP (Glucose-Dependent Insulinotropic Polypeptide) is foundational for anyone reviewing peptide research literature, comparing different research compounds, or following regulatory developments in this field. The term appears across pharmacology textbooks, FDA documentation, and clinical trial reports.
Where to learn more
For deeper context, see our peptide research articles: